GlassScriptPhysician profile
Scott William Hall
NPI 1013913292
$23,572.37
in general payments reported to CMS, 2019-2025
40 companies · $451 in 2025
The $451 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $6,657 · 2021: $1,683 · 2022: $1,822 · 2023: $277 · 2024: $379 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578 · Consulting Fee: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.43 |
| Consulting Fee | $529.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $10,299.69 | 2019 | |
| Janssen Scientific Affairs, LLC | $4,252.96 | 2020-2025 | Talvey |
| Celgene Corporation | $1,856.31 | 2019-2025 | Reblozyl |
| Tg Therapeutics, INC. | $1,665.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $1,631.66 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $552.92 | 2019-2022 | |
| Genzyme Corporation | $336.31 | 2019-2023 | |
| Janssen Biotech, INC. | $271.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $232.07 | 2019-2025 | Calquence, Enhertu |
| Tersera Therapeutics LLC | $229.00 | 2024 | |
| Verastem, INC. | $218.39 | 2019-2020 | |
| Genentech USA, INC. | $179.32 | 2019-2023 | |
| Amgen INC. | $165.33 | 2019-2020 | |
| Abbvie INC. | $139.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $128.04 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.